LO3A Stock Overview
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Lonza Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF53.50 |
| 52 Week High | CHF61.00 |
| 52 Week Low | CHF32.00 |
| Beta | 0.64 |
| 1 Month Change | -3.60% |
| 3 Month Change | 13.35% |
| 1 Year Change | -8.55% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -7.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| LO3A | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 1.9% | 1.3% | 2.5% |
| 1Y | -8.5% | -11.7% | 5.4% |
Return vs Industry: LO3A exceeded the German Life Sciences industry which returned -11.7% over the past year.
Return vs Market: LO3A underperformed the German Market which returned 5.4% over the past year.
Price Volatility
| LO3A volatility | |
|---|---|
| LO3A Average Weekly Movement | 4.7% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LO3A has not had significant price volatility in the past 3 months.
Volatility Over Time: LO3A's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 18,000 | Albert Baehny | www.lonza.com |
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing.
Lonza Group AG Fundamentals Summary
| LO3A fundamental statistics | |
|---|---|
| Market cap | €38.85b |
| Earnings (TTM) | €669.32m |
| Revenue (TTM) | €6.87b |
58.0x
P/E Ratio5.7x
P/S RatioIs LO3A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LO3A income statement (TTM) | |
|---|---|
| Revenue | CHF6.72b |
| Cost of Revenue | CHF4.31b |
| Gross Profit | CHF2.40b |
| Other Expenses | CHF1.75b |
| Earnings | CHF654.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | 9.07 |
| Gross Margin | 35.77% |
| Net Profit Margin | 9.74% |
| Debt/Equity Ratio | 29.4% |
How did LO3A perform over the long term?
See historical performance and comparison